logo
Book a meeting
Arkayli Biopharma

Arkayli Biopharma

Pharmaceuticals, 200 Berkeley St, Madison, Wisconsin, 02116, United States, 1-10 Employees

arkayli.com

  • LinkedIn

phone no Phone Number: +16*********

Who is ARKAYLI BIOPHARMA

Our mission is to develop novel medications with precision drug delivery systems to enhance efficacy and maximize safety of treatments for children and adults with vascular anomalies. Our...

Read More

lock icon Get Full Access
map
  • 200 Berkeley St, Madison, Wisconsin, 02116, United States Headquarters: 200 Berkeley St, Madison, Wisconsin, 02116, United States
  • 2022 Date Founded: 2022
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies
  • Seth Reno CEO:   Seth Reno

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from ARKAYLI BIOPHARMA

Arkayli Biopharma Org Chart and Mapping

Seth Reno

Seth Reno

President and CEO

See Full Org Chart arrow
email-formate-icon
View Email Formats for Arkayli Biopharma
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Arkayli Biopharma

Answer: Arkayli Biopharma's headquarters are located at 200 Berkeley St, Madison, Wisconsin, 02116, United States

Answer: Arkayli Biopharma's phone number is +16*********

Answer: Arkayli Biopharma's official website is https://arkayli.com

Answer: Arkayli Biopharma's revenue is $5 Million to $10 Million

Answer: Arkayli Biopharma's SIC: 2834

Answer: Arkayli Biopharma has 1-10 employees

Answer: Arkayli Biopharma is in Pharmaceuticals

Answer: Arkayli Biopharma contact info: Phone number: +16********* Website: https://arkayli.com

Answer: Our mission is to develop novel medications with precision drug delivery systems to enhance efficacy and maximize safety of treatments for children and adults with vascular anomalies. Our lead product candidate, ARK001, has the potential to be the first FDA-approved non-systemic topical (applied to the skin) treatment for infantile hemangioma (IH). ARK001 has the potential to change the approach to care for IH, allowing pediatricians and dermatologists to treat before the IH requires systemic therapy.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access